Cayman DCP-LA

DCP-LA is a derivative of linoleic acid (Item No. ) and a potent activator of PKCε. It activates PKCε with a greater than 7-fold stronger potency over PKCα, βI, βII, γ, δ, μ, η, and ζ in a cell-free assay. DCP-LA activates PKC in PC12 cells in a concentration-dependent manner, an effect that is blocked by the PCK inhibitor bisindolylmaleimide I (Item Nos. | ) and a PCKε-selective peptide inhibitor. It decreases intracellular levels of amyloid-β (Aβ) in Neuro2 neuroblastoma cells transfected with human APPSwe/PS1Δ9. DCP-LA also stimulates hippocampal glutamate release, striatal dopamine release, and hypothalamic serotonin release in rat brain slices in a PKC- and α7-containing nicotinic acetylcholine receptor-dependent manner. In vivo, DCP-LA (3 mg/kg, i.p.) prevents synaptic loss and amyloid plaque formation and decreases escape latency in the Morris water maze in the 5XFAD transgenic mouse model of Alzheimers disease.

WARNING This product is not for human or veterinary use.